StockData

DBV Technologies vs TScan Therapeutics

DBVT and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DBVT and TCRX compare

DBV Technologies is the larger company, worth 315 times as much as TScan Therapeutics ($3.2B against $10.2M).

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −31.6% for DBV Technologies).

TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −5405% at DBV Technologies.

DBV Technologies scores higher on the StockData Score (6 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDBVTTCRX
Size and price
Market cap$3.2B$10.2M
Share price$10.27$0.151
Change, 1 year−21.4%−86.3%
Change, 5 years71.2%−98.3%
Beta (5Y)−0.082.15
Employees125142
StockData Score
Total score6 (better)4
Valuation score03 (better)
Growth score00
Performance score00
Health score6 (better)1
Dividend score00
Valuation
P/S842×1.4× (better)
P/B21.7×0.1× (better)
FCF yield−5.9% (better)−1157%
Fair value–$1.36
Margin of safety–88.9%
Growth
Revenue growth (TTM)−31.6%2.2% (better)
Revenue growth, 5Y average−13.0%56.9% (better)
Profitability
Operating margin−5432%−1695% (better)
Net margin−5405%−1655% (better)
FCF margin−4998%−1666% (better)
Return on equity−206%−95.8% (better)
Financial health
Debt / equity0.000.47 (better)
Interest coverage–−43.2×
Current ratio3.243.37 (better)
Altman Z-score24.42 (better)−6.31
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.8%53.5%
Held by insiders12.1%32.8%
Insider net buying, 12 months−$15.5M$146K (better)
Superinvestors holding1–
Short interest, % of float–4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.